Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Cash Flows (Unaudited)

v3.22.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 6 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Cash flows from operating activities:    
Net loss $ (14,409,480) $ (11,916,347)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 6,422 6,163
Acquired in-process research and development 285,627
Amortization of operating lease right-of-use asset 45,213 40,146
Share-based compensation 682,966 740,110
Non-cash interest 624
Change in operating assets and liabilities:    
Prepaid expenses and other current assets (90,659) (371,464)
Other assets 82,959
Accounts payable 255,121 (144,027)
Accrued expenses (205,474) 832,058
Operating lease liability (45,529) (39,507)
Deferred income (225,119)
Net cash used in operating activities (13,700,912) (10,769,285)
Cash flows provided by investing activities:    
Purchase of in-process research and development (285,627)
Net cash used in investing activities (285,627)
Cash flows from financing activities:    
Proceeds from the issuance of common stock, net of issuance costs 10,178,627
Proceeds from the exercise of warrants 2
Repayments of related-party notes (20,436)
Net cash provided by financing activities 10,158,193
Net decrease in cash (13,986,539) (611,092)
Cash, beginning of period 27,622,067 7,349,903
Cash, end of period 13,635,528 6,738,811
Supplemental disclosure of non-cash financing activities:    
Net settlement of warrants 243
Issuance of common stock on vesting of restricted stock units $ 1